We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




Electroporation Device Helps Treat Solid Tumors

By HospiMedica International staff writers
Posted on 27 Apr 2021
Print article
Image: TAVO and electroporation kill cancer cells (Photo courtesy of OMS)
Image: TAVO and electroporation kill cancer cells (Photo courtesy of OMS)
A novel device disrupts the membrane of cancer cells, significantly increasing uptake of anti-cancer agents.

The OncoSec Medical System (OMS; San Diego, CA, USA) OMS electroporation device is intended for use during chemotherapy and immunotherapy by opening pores within the membranes of target cancer cells, improving therapy effectiveness and reducing systemic toxicity. The electroporation platform consists of a generator that creates short-duration pulsed electrical fields which are delivered via a hand-held applicator at a specific voltage through a series of thin electrode needles. The generator and applicator create a rotating array of pulses that uniformly subject the targeted cell membranes to electroporation.

The electroporation enables delivery of tavokinogene telseplasmid (TAVO) directly into the tumor microenvironment, producing a controlled, localized expression of interleukin-12 (IL-12), a naturally occurring pro-inflammatory cytokine that promotes T-cells and tumor-infiltrating lymphocyte (TIL) recruitment, enhancing response to the immune checkpoint PD-1 and converting anti-PD-1 non-responders to responders. In addition to drug delivery, the platform also supports the GenPulse gene electrotransfer device. The electric fields are inert, and dissipate once the electroporation is stopped.

“We are confident that our gene electrotransfer technology will emerge as a preferred choice for therapeutic gene delivery in patients with advanced cancer for whom currently available treatment options have little or no effect,” said Daniel O'Connor, CEO of OncoSec. “The efficiency at which gene electrotransfer delivers therapy, along with a highly favorable safety profile and ease of use, make it an ideal choice for drug delivery.”

Results from recently completed clinical studies of TAVO have demonstrated a local immune response, and subsequently, a systemic effect as either a monotherapy or combination treatment approach along with an acceptable safety profile. In addition to TAVO, OncoSec is identifying and developing new DNA-encoded therapeutic candidates and tumor indications for use with its Visceral Lesion Applicator (VLA), designed to target deep visceral lesions, such as liver, lung, or pancreatic lesions.

Related Links:
OncoSec Medical System

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Stereotactic Ultralight System
SUSy

Print article

Channels

Critical Care

view channel
Image: The permeable wearable electronics developed for long-term biosignal monitoring (Photo courtesy of CityUHK)

Super Permeable Wearable Electronics Enable Long-Term Biosignal Monitoring

Wearable electronics have become integral to enhancing health and fitness by offering continuous tracking of physiological signals over extended periods. This monitoring is crucial for understanding an... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.